论文部分内容阅读
目的:观察应用输血治疗的恶性血液病化疗患者外周血T细胞亚群及NK细胞活性,探讨去白细胞输血对恶性血液病患者免疫活性细胞的影响。方法:将120例化疗期间需要接受输血治疗的恶性血液病患者分为2组:A组59例接受去白细胞输血;B组61例接受常规输血。2组每次的输血量、输血次数及化疗方案基本相同。对2组治疗前后的T细胞及NK细胞活性进行检测,并与对照组进行比较。结果:①恶性血液病患者各项免疫活性细胞表达均低于对照组(P<0.01);②治疗前A、B2组免疫活性细胞表达差异无统计学意义,治疗后A组的NK细胞活性明显高于B组(P<0.01);A组治疗后CD3+、CD4+、CD4+/CD8+、NK细胞活性明显高于治疗前(P<0.05);③B组发生非溶血性发热反应(NHFTR)率明显高于A组(P<0.01)。结论:T细胞亚群、NK细胞活性在恶性血液病患者中受到明显抑制;与常规的输血治疗方法相比,去白细胞输血能明显改善恶性血液病患者的细胞免疫功能,尤其是对NK细胞,并能有效预防NHFTR。
OBJECTIVE: To observe the T lymphocyte subsets and NK cell activity in peripheral blood of patients with hematologic malignancies treated with transfusion and explore the effect of leukocyte transfusion on immune active cells in patients with hematologic malignancies. Methods: A total of 120 patients with hematologic malignancies undergoing transfusion therapy were divided into two groups: 59 patients in group A received leukocyte transfusion, and 61 patients in group B received routine blood transfusion. 2 groups of blood transfusion, blood transfusion and chemotherapy program is basically the same. The T cell and NK cell activity of two groups before and after treatment were detected and compared with the control group. Results: (1) The expression of immunocompetent cells in patients with hematologic malignancies was lower than that in the control group (P <0.01); ② There was no significant difference in the expression of immunocompetent cells between groups A and B2 before treatment (P <0.01). The activity of CD3 +, CD4 +, CD4 + / CD8 + and NK cells in group A was significantly higher than that before treatment (P <0.05). The rate of non-hemolytic fever (NHFTR) in group B was significantly higher than that in group B In group A (P <0.01). CONCLUSION: T cell subsets and NK cell activity are significantly inhibited in patients with hematologic malignancies. Compared with conventional transfusion therapy, leukocyte transfusion can significantly improve cellular immune function in patients with hematologic malignancies, especially in NK cells, And can effectively prevent NHFTR.